A randomized double -blind placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with polymyalgia rheumatic

Brief description of study

In this study, the study drug, sarilumab, is investigational and needs to be tested to know if it is safe and effective for your disease, polymyalgia rheumatica (PMR). An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). The purpose of this study is to evaluate if sarilumab is safe and effective in subjects with PMR and to understand how well your disease responds to this investigational drug.

Clinical Study Identifier: s18-00862
ClinicalTrials.gov Identifier: NCT03600818
Principal Investigator: David H. Goddard.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.